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Abstract
Cancer is largely marked by genetic instability. Specific inhibition of individual proteins or signalling pathways that regulate
genetic stability during cell division thus hold a great potential for cancer therapy. The Aurora A kinase is a Ser/Thr kinase
that plays a critical role during mitosis and cytokinesis and is found upregulated in several cancer types. It is functionally
regulated by its interactions with TPX2, a candidate oncogene. Aurora A inhibitors have been proposed as anticancer drugs
that work by blocking its ATP binding site. This site is common to other kinases and hence these inhibitors lack specificity
for Aurora A inhibition in particular, thus advocating the need of some alternative inhibition route. Previously, we identified
TPX2 as a cellular target for withanone that selectively kill cancer cells. By computational approach, we found here that
withanone binds to TPX2-Aurora A complex. In experiment, withanone treatment to cancer cells indeed resulted in
dissociation of TPX2-Aurora A complex and disruption of mitotic spindle apparatus proposing this as a mechanism of the
anticancer activity of withanone. From docking analysis, non-formation/disruption of the active TPX2-Aurora A association
complex could be discerned. Our MD simulation results suggesting the thermodynamic and structural stability of TPX2-
Aurora A in complex with withanone further substantiates the binding. We report a computational rationale of the ability of
naturally occurring withanone to alter the kinase signalling pathway in an ATP-independent manner and experimental
evidence in which withanone cause inactivation of the TPX2-Aurora A complex. The study demonstrated that TPX2-Aurora
A complex is a target of withanone, a potential natural anticancer drug.
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Introduction
The most crucial step in a cell cycle progression is the proper
segregation of sister chromatids during mitosis. This process
involves the formation of a highly dynamic bipolar array called
mitotic spindle through the reorganization of the interphase
microtubules. In animal cells, the separation of centromeres
initiates this spindle assembly process that involves changes in the
functional properties of many microtubule-associated proteins
[1,2]. In several cases, these changes are caused by reversible
phosphorylation. Many protein kinases and phosphatases show at
least transient association with either centrosomes or spindle
microtubules [3]. The Aurora A kinase is a similar Ser/Thr kinase
that has been found to play critical role during mitosis and
cytokinesis [4,5,6]. It mainly associates with the centrosome and
the spindle microtubules during mitosis, and functions in
centrosome maturation, spindle assembly, maintenance of spindle
bipolarity, and mitotic checkpoint control.
Regulation of Aurora A protein is a complex mechanism that
involves an interaction between the small GTPase Ran and the
spindle protein TPX2 [7,8]. Firstly, TPX2 (targeting protein for
Xenopus kinesin-like protein 2) is released by GTPase Ran from
importins a and b. The binding of TPX2 to Aurora A causes the
activation of the kinase by stimulating its autophosphorylation and
thereby protecting it from the inhibitory action of PP1 [9,10].
Furthermore, TPX2 binding targets the protein to spindle
microtubules at the pole [11]. The human Aurora A gene,
STK15 is present in the genomic region (20q13.2) and is often
amplified in certain cancers [12]. Enhanced activity of Aurora A
protein has been reported in several cancer types like prostate
[13], ovarian [14], bladder [15], gastric [16], laryngeal [17],
pancreatic [18] and breast carcinoma [19]. Constitutive overex-
pression of an active mutant of Aurora A caused neoplastic
transformation in rat1 cells, thus indicating that Aurora A is an
oncogene [20]. Furthermore, its interaction with tumour suppres-
sors such as p53, BRCA1 and LATS2 also suggests its connection
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30890to oncogenesis. TPX2 is also a proliferation-associated protein that
was found to be over-expressed in BPDE-transformed human
bronchial epithelial (16HBE-C) cells [21]. It is overexpressed in
liver, lung, prostate and pancreatic cancers [22] and has been
identified as a candidate oncogene on 20q11.2 showing copy
number-driven over-expression in non-small-cell lung cancer and
PDAC [23]. TPX2 targeting siRNAs caused cell cycle arrest and
apoptosis in cancer cell lines [24]. A siRNA library based
screening revealed that TPX2 is one of the three genes that
significantly reduced the survival of multiple human tumor cell
lines [25].
In the recent past, several Aurora A kinase inhibitors have been
developed as potential anti-cancer drugs. Specificity of such drugs
has been a major issue that needs to be validated in experimental
and clinical settings. While the mainstream approach focuses on the
blocking of ATP-binding site of Aurora A kinaseby the inhibitor, an
alternate way would be to block its bindingto the co-factors or other
proteins that mediate its function independent to its ATP binding.
Most of the Aurora A inhibitors identified so far block the ATP
binding site of all the protein kinases and not particularly of Aurora
A [26], and hence pose complexity for their clinical trials and use.
Three novel Aurora kinase inhibitors have recently been described
i.e., Hesperadin [27], ZM447439 [28] and VX-680 [29]. All these
three drugs have been designed to target the ATP-binding site of
Aurora kinase, so they inhibit all the three Aurora kinase family
members- Aurora A, B and C showing a similar phenotype when
tested in cell-based assays [26]. Since TPX2-Aurora A complex has
been predicted to have oncogenic properties [30], an alternate
approach to interfere with the ability of Aurora A to interact with
TPX2 may hold promise to identify novel anticancer drugs.
We had previously identified anticancer activity in the alcoholic
extract (i-Extract) of Ashwagandha (Withania somnifera) leaves
[31,32] and elucidated the mode of actions of its pharmacolog-
ically active metabolites [33,34,35,36]. By cell-based assays linked
to the chemical analysis of the plant extract, we demonstrated that
the i-Extract and its component withanone kill human cancer cells
selectively, mediated by activation of tumor suppressor proteins
and ROS pathway [31,37]. In order to investigate the cellular
targets for anticancer activity of i-Extract and withanone, we
performed loss-of-function screening using siRNA and random-
ized ribozyme libraries [31,37], and identified candidate proteins.
In the screening using ribozymes, we identified TPX2 as a
candidate cellular target. TPX2 knockdown by siRNA indeed
resulted in increased survival of cancer cells subsequent to the
treatment with i-Extract [37]. Since TPX2 function is closely
linked to Aurora A (TPX2-Aurora A complex being oncogenic),
we undertook a joint computational and experimental approach to
predict and validate the effect of withanone (an active anticancer
component in i-Extract) on TPX2-Aurora A complex.
Results and Discussion
Human gene loci, 20q11 and 20q13, that harbor TPX2 and
Aurora A genes are often amplified in tumors [38,39]. We
investigated the status of Aurora A and TPX2 in 19 human cancer
cell lines, 4 kinds of normal human cells along with 15 healthy
subjects by PCR using gene specific primers. Both TPX2 and
Aurora A were found to be amplified in large majority of cancer
cells (Figure 1 and data not shown).
Semi-flexible docking of withanone into TPX2-Aurora A
In order to explore the possibility of disruption of the complex
between Aurora A and TPX2, we first carried out semi-flexible
molecular docking studies with the protein crystal structure. Before
docking, the structures of receptor macromolecules were mini-
mized in Steepest Descent followed by Conjugate Gradient
methods using Accelrys Discovery studio. Figure 2A shows the
docked ligand withanone inside the interfacial cavity of the two
domains. Withanone gets buried inside the pocket as depicted by
mesh representation in Figure 2B. For this particular configuration
the binding energy of the ligand with receptor is 27.18 Kcal/mol.
The binding of withanone to the association complex is
characterized by H-bonding between a terminal carboxyl group
of the ligand and the side chain His 280 of Aurora A. Side chain
amino hydrogens of Lys 38 of TPX2 were also found H-bonding
with this carboxyl terminal of withanone (Figure 3A). The lengths
of the two H-bonds formed are 2.47 and 4.55 A ˚. The residue His
280 of Aurora A has been reported as one of the critical residues
being involved in interacting with Phe 35 of TPX2 [40]. The other
end of withanone also forms H-bond with the side chain hydroxyl
group of Thr 288 and amino group of Arg 180 with bond
distances of 3.13 and 2.18 A ˚, respectively. It has also been
reported that the residues Trp 34 and Phe 35 of TPX2 are
responsible for intermolecular hydrophobic interactions with His
187 and His 280 of Aurora A. In the present docked structure,
withanone is found disrupting the van der Waals interactions
present in the association domain (Figure 3B). It was also observed
that withanone sets up its own interactions with Phe 35, Lys 38 of
TPX2 and Arg 180, Ile 184, His 280 of Aurora A (Figure 3C).
Strong interactions formed by withanone with these particular
residues would result in building steric as well as thermodynamic
barriers to the association of the two subunits, thus providing
hindrance for binding of TPX2 to Aurora A at these particular
residues. This obstruction would pave way to unlikely complex
formation capability yielding in either the formation of a deformed
complex or at extreme no complex formation at all. Moreover, the
deformed complex would be thermodynamically much less stable
as compared to the native complex owing to the non-availability of
withanone occupied hydrophobic interaction forming residues of
Aurora A. In both cases, the TPX2-Aurora A complex would not
get assembled to its catalytically active form. These non-covalent
interactions help stabilize the binding of the ligand with the
macromolecule by lowering the energy of the system. The absence
of active dual subunit complex would result in disposition of
Aurora A to autophosphorylation and inhibitory action of PP1.
This would ultimately lead to non-translocation of Aurora A to the
spindle microtubules as the poles, thus arresting its nefarious acts.
Flexible docking of withanone into active TPX2-Aurora A
complex
Docking of withanone performed on the receptor in which the
key residues responsible for holding up of the two domains were
kept flexible also provided interesting results. Four clusters were
obtained for Genetic Algorithm run for generation of ten models.
Large negative binding energies were obtained for all the clusters
as evident from Table 1. The lowest binding energy obtained using
this docking mode was more than twice as low as that of the
energy obtained from semi-flexible binding of withanone to the
rigid receptor. In the undocked protein, the ring side chains of the
two amino acids Phe 35 of TPX2 and His 280 of Aurora A were
forming edge to face pi-pi interactions. But the presence of docked
withanone disrupts this crucial non-covalent bonding in Cluster 1.
As shown in Figure 4A, the ring group of withanone itself forms
stacking intermolecular interactions with the rings of His 280 and
Pro 282. This also adds to lowering of the energy of the complex as
the stacking forces which are more energetically stable than the
perpendicular ones. Withanone closely interacts with Arg 180 and
Ile 184 also of Aurora A. The high binding energy obtained for
TPX-Aurora A Targeting by Withanone
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receptor resulted in formation of a very extensive H-bonding with
the ligand Figure 4B. The terminal hydroxyl group and epoxy
group of withanone was found H-bonding with Arg 180 with bind
distances of 3.60 and 3.46 A ˚. The middle hydroxyl bonds with Pro
282 and Ser 284 and the ring lactone group interacts with Ser 282.
The placing of withanone among these residues can be considered
responsible for the enzyme inhibition, since the segment
containing residues 274–299 has been described as kinase
activation segment [40].
The results obtained from docking of withanone into the active
complex, with a majority of H-bond and hydrophobic interaction
forming residues kept flexible, clearly showed that withanone blocks
the intermolecular hydrophobic interactions between TPX2 and
Aurora A at the residues which are significantly involved in
formation of the active complex. The large value of binding energy
for Cluster 1 (216.27 Kcal/mol) involved in binding of withanone
to the complex consolidates the thermodynamic stability of the
binding. These results substantiate the hypothesis that withanone
possess thepotentialtodisarraytheactivecomplex bydisruptingthe
stability of attachment of TPX2 to Aurora A, being accounted by
hydrophobic and H-bond interactions.
MD simulations in water
The TPX2/Aurora A/withanone protein-drug binding complex
with the binding energy of 27.34 kcal/mol obtained using
ParDOCK was used for carrying out MD simulations. After the
MD simulation, we calculated RMSDs between Ca of TPX2-Aurora
A complex trajectories recorded every 1 ps and Ca of their X-ray
crystal structure. The RMSDs for the trajectories of the TPX2-
Aurora A complexed with withanone were also calculated using its
initial PDB structure as a reference. The results in Figure 5A show
that the RMSD of the complex has achieved a stationary phase
during the later stage of the simulation and is always less than 2.5 A ˚
fortheentiresimulationlengthsuggestingthestabilityofthecomplex,
while the RMSDs of the protein from its initial X-ray PDB structure
kept increasing and is greater than that of the complex. It was also
found that the energy of the complex (blue) is always lower than that
of the protein alone (red) throughout the length of the simulation
(Figure 5B). This rules out the possibility of the complex getting
activated in the presenceof ligand. The simulation lengths used in the
entire study were long enough to allow rearrangement of side chains
of the native as well as the drug complexed protein to find their most
stable binding modes. In conclusion, the present MD simulations
support thehypothesis that withanoneisquitea probable and aworth
small molecule ligand for targeting/inhibiting the kinase association
complex. These results would be valuable for further designing non-
covalent type inhibitors with high specificity and potent activity.
Validation using experimental assays
We finally validated the computational predictions using cell-
based assays. Human cancer cells were first treated with
Figure 1. mRNA expression of Aurora A and TPX2 as analysed by RT-PCR is shown. Blood and fibroblasts represent the normal samples
whereas the others are the cancer cell lines as indicated (A). Quantitation of the signals obtained by RT-PCR shown in B signified increase both in
TPX2 and Aurora A in cancer cell lines.
doi:10.1371/journal.pone.0030890.g001
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examined by RT-PCR, Western blotting and immunocytostaining
analyses. RT-PCR analysis of Aurora A and TPX2 in control and
withanone treated MCF 7 and U2OS cells showed only a minor
difference in the expression level of both mRNAs (Figure 6A and
data not shown). Western blotting with specific antibodies revealed
significant decrease in the protein levels of both Aurora A and
TPX2 in response to withanone in the both the cell lines (Figure 6B
and data not shown) examined suggesting that the decrease may
reflect their enhanced degradation as a result of disruption of their
complex formation as predicted by computational analysis. We
next performed immunocytostaining to investigate the TPX2-
Aurora A complex and mitotic spindle formation in control and
withanone-treated cells. As shown in Figures 6C and 6D,
withanone-treated MCF 7 cells showed decrease in the number
of cells with co-localized Aurora A and TPX2 and increase in
number of cells showing the disruption of mitotic spindle. Similar
data were obtained in U2OS cells. We next generated derivatives
of MCF 7 and U2OS cells that overexpressed either TPX2 or
Aurora A (Figures 7A and 7B) and performed an extensive
imaging analysis on Aurora A-TPX2 colocalization and mitotic
spindle formation in both control and withanone treated cells
(Figure 7C). The cells when treated with withanone showed
increase in the number of cells with seggregated proteins and
disrupted spindle formation (Figure 7A–C) suggesting that increase
Figure 2. Docking representations of Withanone. (A) Ligand
docked into the receptor cavity (B) Docked Ligand inside the pocket of
receptor mesh.
doi:10.1371/journal.pone.0030890.g002
Figure 3. Interactions of docked withanone with rigid Aurora
A/TPX2 receptor. (A) H-Bond interactions of the docked ligand with
the macromolecule residues (B) Docked withanone disrupting the crucial
non-covalent interactions already present in the undocked protein (C)
Withanone forming hydrophobic interactions with the receptor.
doi:10.1371/journal.pone.0030890.g003
TPX-Aurora A Targeting by Withanone
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overcome the effect of withanone. Consistent to these findings, the
overexpressing derivatives underwent growth arrest in response to
the withanone treatment. In order to further substantiate the
disruption of Aurora A-TPX2 active complex formation by
withanone, we investigated the kinase activity of the complex in
control and treated cells. Phosphorylation of Aurora A and its
subtrate histone H3 was examined in control and withanone
treated cells by using phosphorylation specific antibodies. As
shown in Figure 7D, there was a significant decrease in
phosphorylated histone H3 in withanone treated cells. Further-
more, Aurora A and TPX2 overexpressing cells that showed
disruption of Aurora A-TPX2 complex formation (Figure 7C) and
growth arrest (data not shown) in response to withanone treatment
also showed similar decrease in the level of phosphorylated histone
H3 (Figure 7D). These data demonstrated that withanone
abrogates TPX2-Aurora A complex formation, inactivates the
Aurora A-TPX2 kinase complex resulting in the disruption of the
mitotic spindle formation and inhibits cancer cell division. It,
therefore, could be a potential anticancer drug.
Materials and Methods
Ligand and receptors
The crystal structure of the TPX2-Aurora A association domain
[PDB: 3E5A] [40] was obtained from the Protein Data Bank
(PDB) [41]. This structure was then subjected to certain
modifications which would make it suitable for docking. These
included the use of repairCommands module of AutoDock to
supplement a number of missing atoms, removal of water
molecules to clean the crystal structure and addition of H-atoms
to these target proteins for correct ionization and tautomeric states
of amino acid residues. The modified structure was used for all
flexible and semi-flexible docking studies. The ligand molecule
withanone [PubChem: 21679027] was retrieved from NCBI-
PubChem Compound database [42]. The structure of this
compound is shown in Figure S1. The energy of the ligand
molecule and receptors were minimized in Steepest Descent and
Conjugate Gradient methods using Accelrys Discovery Studio
(Version 1.7, Accelrys Software Inc.). Each of the minimization
methods were carried out with CHARMm force field.
Structural aspects of TPX2-Aurora A association complex
The structural features of the receptor macromolecule consid-
ered in our study [PDB: 3E5A] have been described in detail
elsewhere [40] by the depositors of the crystal structure to the
Protein Data Bank. Briefly, the structure includes the catalytic core
of the Aurora A kinase (residues 123–387) and two segments of
TPX2 (residues 6–21 and 26–43). The four missing residues of
TPX2 (residues 22–25) have not been modelled due to the absence
of ordered electron density. This fragment of TPX2 (residues 1–
43) is independently capable of binding, kinase activation, and
protection from dephosphorylation of Aurora A kinase. Further-
more, Aurora A shows increased catalytic efficiency due to the
addition of TPX2 (residues 1–43) [43]. The Aurora A catalytic
core (residues 123–387) comprises of an N-terminal lobe (residues
123–210) and a large C-terminal lobe (residues 217–387). The
active site is located at the interface between the lobes which
includes the ATP binding site, the catalytic base (Asp256), and the
kinase activation segment (residues 274–299). The binding of
TPX2 with Aurora A is in two stretches, similar to that in TPX2/
Aurora A/ADP structure [11]. The binding of upstream stretch
Figure 4. Interactions of docked withanone with flexible
receptor. (A) The docked withanone forming intermolecular interac-
tions (B) Withanone forming extensive H-bonds with the residues of
flexible receptor.
doi:10.1371/journal.pone.0030890.g004
Table 1. Clustering results obtained from flexible docking of withanone into TPX2-Aurora A complex.
Receptor
No. of AutoDock
clusters
a,b Cluster rank
b
No. of structures
in the cluster
Lowest binding
energy of cluster
Energy range
within cluster
13 216.27 216.27 to 214.95
TPX2-Aurora A complex 4 (10) 2 2 215.65 215.65 to 214.58
34 215.61 215.61 to 214.35
41 214.63 214.63 to 214.63
aNumber of GA runs are shown in parentheses.
bClustering is done with RMS tolerance of 5.0 A ˚.
doi:10.1371/journal.pone.0030890.t001
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extended conformation while the downstream stretch (residues 26–
43) forms an a-helical conformation that interacts with both helix
aC and the activation segment of Aurora A. The two Aurora A
binding motifs of TPX2 are connected by a flexible linker
(disordered in the structure). The conserved residues Tyr8, Tyr10,
Ala12, Phe16, Ile17, Phe19, Trp34, Phe35 and Ala39 of TPX2
interact closely with the Aurora A catalytic core.
Semi-flexible docking
AutoDock 4.0 suite was used as molecular-docking tool in order
to carry out the docking simulations [44]. Several studies report
the comparison of AutoDock with other docking programs.
AutoDock has been found to be able to locate docking modes
that are consistent with X-ray crystal structures [45,46]. AutoDock
helps to simulate interactions between substrates or drug
candidates which act as ligands and their macromolecular
receptors of the known three dimensional structures. AutoDock
allows full ligand flexibility, more than that described anywhere
else [44]. In our docking simulations we used the TPX2-Aurora A
association domain structure to perform semi-flexible docking,
with the ligand withanone made flexible while keeping the
receptor macromolecule rigid. The flexibility of ligand molecule
gives it the freedom to search from six degrees of rotational and
translational freedom and an arbitrary number of torsional
degrees of freedom. A random perturbation to each is applied at
each time step, and the interaction energy was evaluated for the
new location and conformation [47].
Flexible docking
One of the characteristic features of AutoDock 4.0 is that it
allows side chains in the proteins to be flexible and can
optionally model flexibility in target macromolecule. Thus,
flexibility of receptor molecule was also exploited in docking
studies by making use of AutoDock flexres scripts. Our
simulations are based on assumption that the ligand which
arrives at the binding site formed by the two chains of receptor
molecule would try to associate with them in order to minimise
the energy of the system. The key residues of Aurora A and
TPX2 chains which form critical interactions with the corre-
sponding residues in the two chains as reported [40] were made
flexible to prove the above said assumption. This helped us in
observing different interaction modes of receptor with the ligand
as well as the rearrangements that follow. The peptide bonds of
the amino acids whose side chains were kept flexible were kept
‘inactive’ and ‘non-rotatable’.
Figure 5. Analysis of MD trajectories. (A) Plot of root mean square deviation (RMSD) of Ca of TPX2-Aurora A (protein) and TPX2/Aurora A /
withanone (complex). RMSDs were calculated using the initial structures as templates. For protein (red) the reference is the PDB structure and for
complex (blue) the reference is the initial docked structure. The trajectories were captured every 2.5 ps until the simulation time reached 6000 ps. (B)
Plot of total energy of TPX2-Aurora A and TPX2/Aurora A/withanone (complex). The energy trajectories of both the protein (red) and the complex
(blue) are stable over the entire length of simulation time with the energy of the complex always lower than that of the protein.
doi:10.1371/journal.pone.0030890.g005
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used for preparing, running and analyzing the docking simula-
tions. Protein structure used for docking simulations was prepared
by attributing Kollman united atom charges, solvation parameters
and polar hydrogens to the receptor PDB structure. Water
molecules were removed from this structure to make it a free
receptor. Ligands which are not peptides were first assigned a
Gasteiger charge and then non-polar hydrogens were merged.
The use of AutoDock for simulations saves time as it assigns rigid
roots to the ligand automatically as compared to manual picking.
Four bonds in the ligand were made ‘‘active’’ or rotatable. Default
solvation parameters were assigned to the receptor. The energy
scoring grid was prepared as a 40, 40 and 32 Au (x, y, and z) cube.
The spacing between grid points was 0.375 Au.
Selection and representation of docking modes
The Lamarckian Genetic Algorithm (LGA) was chosen to search
for the best conformers. The best docking solution (minimum
docked free energy) is reported by AutoDock for each GA run.
Total number of clusters and the rank of each docking mode (cluster
rank) are also reported in the cluster analysis performed by
AutoDock. Docking modes were selected on the basis of two
criteria: extent of ligands’ associations with the key residues of the
receptor and the thermodynamic stability of the docked complex so
obtained. The lowest energy docking mode that would conform to
the above said two parameters was selected from over 10 GA run
and hence 10 total docking modes. All the AutoDock docking runs
were performed in Intel Core 2 Duo P8400 CPU @ 2.26 GHz of
Sony origin, with 3 GB DDR RAM. AutoDock 4.0 was compiled
andrun under Windows VISTAoperating system.Theoutputfrom
AutoDock and allmodelingstudiesaswell asimagesweregenerated
with PyMOL [48] and Accelerys ViewerLite 5.0. The hydrogen
bonds lengths were measured between the hydrogen and its
assumed binding partner using ViewerLite.
Confirmation of the docking results
The docking results obtained using AutoDock were also
confirmed using ParDOCK [49], which is an all atom energy
based monte carlo docking protocol. Docking using ParDOCK
requires a reference complex (target protein bound to a reference
ligand) and a candidate molecule along with specific mention of
the centre of mass of the cavity on which the ligand is to be
docked.
MD simulations in water
The AMBER v.11 package [50] was used to prepare the protein
and the ligand files as well as for the Molecular Dynamics (MD)
simulations. The binding complexes of TPX2/Aurora A/with-
anone obtained using ParDOCK and the un-docked TPX2-
Aurora A association protein simulated in this study were
neutralized by adding appropriate number of sodium counter-
ions and were solvated in a octahedron box of TIP4PEW water
with a 10 A ˚ distance between the protein surface and the box
boundary [51]. The partial atomic charges for the ligands were
obtained after optimization at the Hartree-Fock level with 6–31G*
basis set and subsequent single-point calculation of the electrostatic
Figure 6. Expression analyses of Aurora A and TPX2 in control and withanone- treated human breast carcinoma (MCF 7) cells. (A) RT-
PCR with gene specific primers and (B) Western blotting with specific antibodies. (C) Immunolocalization of TPX2 and Aurora A in control and
withanone treated MCF 7 cells showing Aurora A (red), TPX2 (green) and co-localization of the two (yellow). (D) Representative high magnification
images of TPX2 and Aurora A immunostaining showing normal and disrupted mitotic spindle in control and withanone treated cells, respectively.
doi:10.1371/journal.pone.0030890.g006
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[52,53]. Force field parameters of the ligands were assigned based
on the atom types of the force field model developed by Cornell et
al [54]. The binding complex was effected with a 750 step
minimization using SANDER module of AMBER in the steepest
descent followed by a 250 step minimization in conjugate gradient.
Then the system was equilibrated beginning with the protein atom
restrained simulations having 200 ps equilibration dynamics of the
solvent molecules at 300 K. Next step involved the equilibration of
the solute molecules with a fixed configuration of the solvent
molecules in which the system was slowly heated from T=0 to
300 K in 60 intervals each involving heating for a 5 K increase in
2.5 ps followed by an equal time duration equilibration step. The
entire system was then equilibrated at 300 K for 200 ps before a
sufficiently long MD simulation for 6 ns at room temperature. The
MD simulations were performed with a periodic boundary
condition in the NPT ensemble at T=298.15 K with Berendsen
temperature coupling [55] and constant pressure P=1 atm with
isotropic molecule-based scaling. We used a time step of 2 fs and a
non-bond interaction cutoff radius of 10 A ˚. MD simulations were
performed on a 320 processors SUN Microsystems clusters at
Supercomputing Facility (SCFBio) at IIT Delhi.
Cell culture and treatment with withanone
Human osteosarcoma cells (U2OS) [56] obtained from American
Type Culture Collection (ATCC) and breast carcinoma cells
(MCF7) [56] obtained from Japanese Collection of Research
Bioresources (JCRB) were cultured in Dulbecco’s modified Eagle’s
minimal essential medium (DMEM), supplemented with 10% fetal
bovineserum at 37uC, inan atmosphereof 5%CO2and 95% airin
a humidified incubator. Cells were treated with withanone at about
60–70% confluency and harvested for following analyses after 48 h
of the treatment. Aurora A and TPX2 overexpressing MCF 7 and
U2OS cells were generated by using retrovirus (pBABE-puro/
Aurora A) and plasmid (pPAGFP-C1/TPX2 ) expression vectors
obtained from Addgene (#8510:hAur-A, gift of Joan Ruderman
and #31226: TPX 2, gift of Patricia Wadsworth).
Aurora A and TPX2 expression analysis
Total RNA from the control and withanone treated cells was
isolated with the RNeasy Mini Kit (QIAGEN). First-strand cDNA
was synthesized using 1 mg RNA with oligo dT as the primer with
MMLV reverse transcriptase. PCR (denaturation-95uC:1 min,
annealing-54uC:1 min and extension-72uC:1 min for 30 cycles)
was performed using specific primers for (i) Aurora-A ( sense 59-
agctccagttggaggtccaaaac-39 and antisense 59-gcctggagacaggat-
gaggtaca-39) and (ii) TPX2 (sense 59-AATGCATCTTCCCCA-
GAGAAAGC-39 and antisense 59-TTCATTCTTTTTCCG-
CATCTCCA-39.7 ml of each PCR product (total 30 ml) was
used for electrophoresis on a 1% agarose gel, stained with
ethidium bromide, visualized with UV light and photographed
(Bio-Rad). For proteins analysis, control and withanone (10–
15 mg/ml) treated cells were lysed in were lysed in NP-40 lysis
buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA,
1% NP-40] supplemented with a protease inhibitor cocktail
(Complete Mini; Roche Diagnostics K.K., Basel, Switzerland).
Aliquots of 20 mg of total protein were resolved on a SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a
polyvinylidene difluoride membrane (Atto Corporation, Tokyo,
Japan) and were probed with anti-Auroa A (polyclonal, Trans-
Genic Inc) and TPX2 (monoclonal clone18D5-1, Abcam)
antibody. Anti-actin antibody (Chemicon International, USA)
Figure 7. Expression analyses of Aurora A and TPX2 in control and overexpressing derivative cell lines. (A) Western blotting of Aurora
A and TPX2 in control MCF 7 and its derivative overexpressing cells, quantitation of the signals is shown in (B). (C) Aurora A and TPX2 co-localization
analysis in control and withanone-treated cells showing decrease in the number of cells with co-localization of the two proteins and the number of
cells with disrupted mitotic spindle in withanone-treated cultures. (D) Western blotting of control and withanone-treated cells with anti-phospho
histone H3 antibody showing decrease indicating the inactivation of Aurora A-TPX2 complex in withanone treated cells.
doi:10.1371/journal.pone.0030890.g007
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linked antibodies against rabbit and mouse IgG raised in donkey
(GE Healthcare Bio-Science AB, Uppsala, Sweden) were used as
secondary antibodies. Immunoreactive bands were detected with
enhanced chemiluminescence reagent (GE Healthcare Bio-Sci-
ence AB) and LAS-3000mini luminoimage analyzer (Fujifilm
Corporation, Tokyo, Japan) following the manufacturer’s instruc-
tions. Quantification of immunoreactive bands was performed
with Image Gauge software (Fujifilm Corporation, Tokyo, Japan).
Immunocytostaining
For immunostaining, cells were plated on glass coverslips placed
in a 12-well culture (10
4 cells /coverslip). After 24 h, when cells
had attached to the surface and spread well, they were treated with
withanone for 48 h following which cells were washed with cold
PBS three times and then fixed with pre-chilled methanol/acetone
(1:1) mixture for 5 min. Fixed cells were washed with PBS twice,
permeabilized with 0.5% Triton X-100 in PBS for 10 min and
blocked with 0.2% BSA/PBS for 10 min. They were incubated
with the anti-Aurora A and TPX2 antibodies for 1 h at room
temperature, washed three times with 0.2% Triton X-100 in PBS,
and then incubated with secondary antibodies (Alexa-594-
conjugated goat anti-rabbit and Alexa 488-conjugated goat anti-
mouse, Molecular Probes). After extensive washings with 0.2%
Triton X-100 in PBS, cells were examined on a Carl Zeiss
microscope (Axiovert 200 M).
Supporting Information
Figure S1 Structures of withanolides. (A) Withanone falls
under the family of compounds known as withanolides which are a
group of naturally occurring C28- steroidal lactones built on an
intact or rearranged ergostane framework, in which C-22 and C-
26 are appropriately oxidized to form a six-membered lactone
ring. The basic structure is designated as the withanolide skeleton
defined as a 22-hydroxyergostan-26-oic acid-26,22-lactone. (B)
Structure of withanone.
(JPG)
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